P1119: CAMRELIZUMAB PLUS LOW-DOSE APATINIB AND PEGASPARGASE FOLLOWED BY RADIOTHERAPY FOR NEWLY DIAGNOSED STAGE I/II NATURAL KILLER/T-CELL LYMPHOMA: A PROSPECTIVE MULTICENTER SINGLE-ARM STUDY
LI Zhi-Ming,
Chuanxu Liu,
Peng Sun,
Shu Tian,
Hao Ding,
Rong Tao
Affiliations
LI Zhi-Ming
1 Sun Yat-sen University Cancer Center, Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China
Chuanxu Liu
2 Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Department of Hematology, Shanghai, China
Peng Sun
1 Sun Yat-sen University Cancer Center, Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China
Shu Tian
4 Eye & ENT Hospital, Fudan University, Department of Radiation Oncology, Shanghai, China
Hao Ding
4 Eye & ENT Hospital, Fudan University, Department of Radiation Oncology, Shanghai, China
Rong Tao
2 Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Department of Hematology, Shanghai, China
